Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Bristol Myers Squibb announced the final analysis of overall survival from the phase III CheckMate-816 study, which evaluated Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Urine test for prostate cancer could be used at home, study finds

Researchers at Vanderbilt and the University of Michigan have shown that an at-home urine test for prostate cancer screening is highly accurate.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

Bristol Myers Squibb announced results of an analysis from the three-arm phase III CheckMate-8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo monotherapy across all lines of therapy, including first-line, for the treatment of microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. At a median follow-up of 47 months, Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in the dual-primary endpoint of progression-free survival as assessed by Blinded Independent Central Review versus Opdivo monotherapy (HR 0.62; 95% CI 0.48–0.81; P = 0.0003).

January 31, 2025

Vol.51 No.04

Drugs & Targets

FDA grants RP1 BLA priority review for advanced melanoma

FDA has accepted the Biologics License Application from Replimune Group Inc. for RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) for patients with advanced melanoma.

January 24, 2025

Vol.51 No.03

Drugs & Targets

FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection

FDA approved Opdivo (nivolumab) and Opdivo Qvantig (hyaluronidase-nvhy) for subcutaneous injection across approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib.

January 10, 2025

Vol.51 No.01

Drugs & Targets

EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC

The European Commission has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer.

January 10, 2025

Vol.51 No.01

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

YOU MAY BE INTERESTED IN

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Urine test for prostate cancer could be used at home, study finds

Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial

FDA grants RP1 BLA priority review for advanced melanoma

FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection

EC approves Opdivo + Yervoy as first-line treatment for MSI-H or dMMR metastatic CRC

Renew today!

Subscriber content

Never miss an issue!

Login